JP5666087B2 - Ｃｎｓ関連疾患の治療のための方法及び組成物 - Google Patents

Ｃｎｓ関連疾患の治療のための方法及び組成物 Download PDF

Info

Publication number
JP5666087B2
JP5666087B2 JP2008505658A JP2008505658A JP5666087B2 JP 5666087 B2 JP5666087 B2 JP 5666087B2 JP 2008505658 A JP2008505658 A JP 2008505658A JP 2008505658 A JP2008505658 A JP 2008505658A JP 5666087 B2 JP5666087 B2 JP 5666087B2
Authority
JP
Japan
Prior art keywords
memantine
composition
pharmaceutically acceptable
acceptable salt
donepezil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008505658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535867A5 (enExample
JP2008535867A (ja
Inventor
グレゴリー・ティー・ウェント
ティモシー・ジェイ・フルツ
Original Assignee
アダマス・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37036831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5666087(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/285,905 external-priority patent/US7619007B2/en
Application filed by アダマス・ファーマシューティカルズ・インコーポレーテッド filed Critical アダマス・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2008535867A publication Critical patent/JP2008535867A/ja
Publication of JP2008535867A5 publication Critical patent/JP2008535867A5/ja
Application granted granted Critical
Publication of JP5666087B2 publication Critical patent/JP5666087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Lubricants (AREA)
JP2008505658A 2005-04-06 2006-04-06 Ｃｎｓ関連疾患の治療のための方法及び組成物 Active JP5666087B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66929005P 2005-04-06 2005-04-06
US60/669,290 2005-04-06
US11/285,905 US7619007B2 (en) 2004-11-23 2005-11-22 Method and composition for administering an NMDA receptor antagonist to a subject
US11/285,905 2005-11-22
PCT/US2006/013506 WO2006121560A2 (en) 2005-04-06 2006-04-06 Methods and compositions for treatment of cns disorders

Publications (3)

Publication Number Publication Date
JP2008535867A JP2008535867A (ja) 2008-09-04
JP2008535867A5 JP2008535867A5 (enExample) 2009-05-21
JP5666087B2 true JP5666087B2 (ja) 2015-02-12

Family

ID=37036831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505658A Active JP5666087B2 (ja) 2005-04-06 2006-04-06 Ｃｎｓ関連疾患の治療のための方法及び組成物

Country Status (17)

Country Link
US (18) US8058291B2 (enExample)
EP (2) EP2243475B1 (enExample)
JP (1) JP5666087B2 (enExample)
KR (1) KR101406456B1 (enExample)
CN (1) CN101247795B (enExample)
AT (1) ATE481096T1 (enExample)
AU (1) AU2006244297A1 (enExample)
BR (1) BRPI0607017B8 (enExample)
CA (1) CA2604052C (enExample)
DE (1) DE602006016934D1 (enExample)
DK (1) DK1874282T3 (enExample)
IL (1) IL186504A0 (enExample)
MX (1) MX2007012374A (enExample)
PL (1) PL1874282T3 (enExample)
RU (1) RU2007140348A (enExample)
WO (1) WO2006121560A2 (enExample)
ZA (1) ZA200709535B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
AU2005215767A1 (en) * 2004-02-13 2005-09-01 Adamas Pharmaceuticals, Inc. Combination of an NMDA receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other CNS disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
BRPI0518396A2 (pt) 2004-12-27 2008-11-18 Eisai R&D Man Co Ltd mÉtodo para estabilizaÇço de droga anti-demÊncia
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
GB0519274D0 (en) * 2005-09-21 2005-11-02 Arakis Ltd The treatment of neurodegenerative diseases
US20090169617A1 (en) * 2006-04-26 2009-07-02 Panagiotis Keramidas Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
EP1886670A1 (en) * 2006-07-05 2008-02-13 Teva Pharmaceutical Industries Ltd Pharmaceutical compositions of memantine
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
TWI491395B (zh) 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
CN109662964A (zh) * 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
US20110251239A1 (en) * 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
US9662347B2 (en) * 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
US20130209549A1 (en) * 2010-07-21 2013-08-15 University Of South Florida Materials and methods for treating neurodegenerative diseases
JP2013539790A (ja) 2010-10-12 2013-10-28 ザ ジョンズ ホプキンス ユニバーシティ メマンチンを含む鎮咳組成物
DE102010053432A1 (de) * 2010-12-06 2012-06-06 Euroimmun Medizinische Labordiagnostika Ag Verfahren zum Nachweis von anti-NMDA-Rezeptor Autoantikörpern zum Einsatz in Diagnoseverfahren
US20120214859A1 (en) * 2011-02-09 2012-08-23 Michela Gallagher Methods and compositions for improving cognitive function
EP2675435A1 (en) * 2011-02-17 2013-12-25 Lupin Limited Sustained release composition of memantine
JP6102739B2 (ja) 2011-08-31 2017-03-29 東洋インキＳｃホールディングス株式会社 貼付剤
MX361372B (es) * 2012-04-18 2018-12-05 Contera Pharma Aps Formulacion farmaceutica disponible por via oral adecuada para manejo mejorado de trastornos del movimiento.
KR20150020250A (ko) 2012-06-19 2015-02-25 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 당뇨병을 치료하기 위한 조성물 및 방법
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014111790A2 (en) * 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
WO2014132215A1 (en) * 2013-02-28 2014-09-04 Lupin Limited Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
JP6429808B2 (ja) * 2013-02-28 2018-11-28 ルピン・リミテッド 特異的なインビトロ溶出プロファイルまたは薬物動態パラメーターを有するドネペジル医薬組成物
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN105377371A (zh) 2013-04-12 2016-03-02 西奈山伊坎医学院 创伤后应激障碍的治疗方法
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US20160220512A1 (en) * 2013-09-15 2016-08-04 Rubicon Research Private Limited Modified release pharmaceutical formulations
JP6360494B2 (ja) * 2013-12-12 2018-07-18 久光製薬株式会社 積層型貼付剤
MX383665B (es) * 2014-02-04 2025-03-14 Forest Laboratories Holdings Ltd Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
TWI602585B (zh) 2014-03-25 2017-10-21 林信湧 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法
SMT202000576T1 (it) * 2014-10-03 2020-11-10 Lachesis Biosciences Ltd Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
HUE055779T2 (hu) 2014-11-04 2021-12-28 Adamas Pharmaceuticals Inc Amantadin a járás javítására szklerózis multiplexben
ITUB20150635A1 (it) * 2015-04-14 2016-10-14 Giuseppe Lotito Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
MX2017014192A (es) * 2015-05-07 2018-08-01 Axovant Sciences Gmbh Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
CN108350071A (zh) * 2015-08-17 2018-07-31 德国神经退行性疾病中心 结合到抗N-甲基-D-天冬氨酸(NMDA)受体抗体的结合区的抗体或抗体片段或非Ig支架
KR101882224B1 (ko) * 2015-09-02 2018-07-26 한국프라임제약주식회사 콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물
CN105326837A (zh) * 2015-10-09 2016-02-17 北京万全德众医药生物技术有限公司 一种盐酸美金刚缓释-多奈哌齐速释复方胶囊
RU2737464C2 (ru) 2015-12-30 2020-11-30 Кориум Интернэшнл, Инк. Системы и способы длительного трансдермального введения
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
JP7174632B2 (ja) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス
JP7071958B2 (ja) 2016-07-27 2022-05-19 コリウム， インコーポレイテッド メマンチン経皮送達システム
KR102424270B1 (ko) 2016-07-27 2022-07-25 코리움, 인크. 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템
CN109789133A (zh) 2016-07-27 2019-05-21 考里安国际公司 多奈哌齐透皮递送系统
WO2018062941A1 (ko) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
EP3558378A4 (en) * 2016-12-22 2020-09-16 Synnerva Ltd. LOW DOSE COMBINATION OF MEDICINAL PRODUCTS FOR THE PREVENTION AND TREATMENT OF NEURAL DAMAGE
ES2982382T3 (es) * 2017-05-19 2024-10-15 Biscayne Neurotherapeutics Inc Composiciones farmacéuticas de liberación modificada de huperzina y procedimientos de utilización de las mismas
CN111372578A (zh) 2017-08-24 2020-07-03 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
JP7543136B2 (ja) * 2017-11-22 2024-09-02 パノラマ リサーチ，インコーポレイティド Ｃｎｓ疾患を治療するためのアミノアダマンチルナイトレート化合物およびそれらの使用
US12071649B1 (en) 2017-12-03 2024-08-27 Nitrase Therapeutics, Inc. Identification of modulators of nitration and therapeutic uses thereof
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
KR102224918B1 (ko) * 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2020208398A1 (es) 2019-04-09 2020-10-15 Laboratorios Bagó S.A. Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
SI3843702T1 (sl) 2019-05-31 2023-12-29 Technimede, Sociedade Tecnico-Medicinal, SA Kombinacija memantina in donepezila v fiksnem odmerku s takojšnjim sproščanjem
US20220354827A1 (en) * 2019-06-28 2022-11-10 The Trustees Of The University Of Pennsylvania Ntranasal dantrolene administration for treatment of alzheimer's disease
US20240216358A1 (en) * 2020-03-30 2024-07-04 Shinkei Therapeutics Llc Transdermal delivery of dextromethorphan
WO2021234475A1 (en) * 2020-05-21 2021-11-25 Pellets Pharma Limited Modified release compositions and methods of memantine hcl extended release, donepezil hcl immediate release pellets
CU24720B1 (es) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US20250012814A1 (en) * 2021-11-01 2025-01-09 Nitrase Therapeutics, Inc. Methods of diagnosing a synucleinopathy
WO2024051844A1 (zh) * 2022-09-09 2024-03-14 北京达尔文细胞生物科技有限公司 用于防治急性期面神经麻痹的药物组合物及其应用
AU2023376163A1 (en) * 2022-11-07 2025-05-29 Rejuvenate Biomed Nv Galantamine minitablets
WO2025063698A1 (en) * 2023-09-18 2025-03-27 Aribio Co. Ltd Lamotrigine and rivastigmine combinations for treating neurodegenerative disorders
WO2025065271A1 (en) * 2023-09-26 2025-04-03 Liangzhu Laboratory Methods and devices for treating depression

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
GB1173492A (en) 1966-02-18 1969-12-10 Upjohn Co Acylamino-Adamantane Derivatives
FR2219159A1 (en) 1973-02-23 1974-09-20 Commissariat Energie Atomique Adamantane nitroxide radicals - antiviral and anticancer agents, also useful in nuclear resonance magnetometry
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4284444A (en) 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4148896A (en) * 1978-02-22 1979-04-10 E. I. Du Pont De Nemours And Company Antidepressant combination
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0350080A3 (en) 1981-04-24 1990-01-24 E.R. Squibb & Sons, Inc. Use of nadolol for inhibiting the onset of migraine headaches
US4346112A (en) 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS584718A (ja) 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS61502760A (ja) 1984-07-24 1986-11-27 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド 粘着性経皮投与層
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US4878913A (en) * 1987-09-04 1989-11-07 Pfizer Hospital Products Group, Inc. Devices for neural signal transmission
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
WO1991006291A1 (fr) 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Preparation a liberation entretenue
DK0747485T3 (da) 1989-11-06 1999-08-16 Cell Genesys Inc Fremstilling af proteiner ved anvendelse af homolog rekombination
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
CA2037178A1 (en) 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
IN172468B (enExample) * 1990-07-14 1993-08-14 Asta Medica Ag
EP0488959A3 (en) 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
DE4236752A1 (de) * 1992-10-30 1994-05-05 Asta Medica Ag Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5648087A (en) * 1993-03-09 1997-07-15 Sanofi Sante Nutrition Animale Anaesthetic pharmaceutical composition comprising a general anaesthetic and selegiline
AU676315B2 (en) * 1993-06-30 1997-03-06 Takeda Chemical Industries Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
DE19510189A1 (de) 1995-03-21 1996-09-26 Hartmut Dr Goebel Verwendung von Amantadin
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
RU2176145C2 (ru) * 1995-05-26 2001-11-27 Пфайзер Инк. Синергическое лечение паркинсонизма
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6095148A (en) * 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
ATE293458T1 (de) 1996-08-23 2005-05-15 Algos Pharm Corp Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
ES2255103T3 (es) * 1996-10-25 2006-06-16 Shire Laboratories Inc. Sistema osmotico de administracion de dosis en forma soluble.
DE19644998C1 (de) * 1996-10-30 1998-06-10 Hanns Prof Dr Ludwig Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
JPH10203966A (ja) 1996-11-21 1998-08-04 Takeda Chem Ind Ltd 徐放性マイクロカプセルおよびその製造法
DE69738966D1 (de) 1996-12-20 2008-10-16 Mcneil Ppc Inc Durch ionenaustauscherharze verabreichte hustenmittel
USRE39744E1 (en) * 1997-03-11 2007-07-24 Daicel Chemical Industries, Ltd. Adamantane derivatives and process for producing them
DK0870757T3 (da) * 1997-04-10 2002-07-15 Pfizer Fluorsubstituerede adamantanderivater
JP2001527554A (ja) * 1997-05-07 2001-12-25 アルゴス ファーマシューティカル コーポレーション 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
DE19834764A1 (de) * 1998-08-01 2000-02-03 Univ Hannover Mittel zur Stabilisierung von Lebensmitteln und kosmetischen Mitteln sowie Verfahren zu dessen Herstellung
MY127946A (en) 1998-08-27 2007-01-31 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
EP1555038B1 (en) 1999-03-03 2011-06-29 Optinose AS Nasal delivery device
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6743211B1 (en) * 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
HK1052297B (zh) 1999-09-14 2008-11-28 Glaxosmithkline Llc 制备水性包被小球粒的方法
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1231877A4 (en) 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN
DE60019334T2 (de) * 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
ES2256082T3 (es) 1999-12-22 2006-07-16 Nektar Therapeutics Al, Corporation Derivados de polimeros hidrosolubles con impedimento esterico.
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
EP1559418A1 (en) 2000-06-26 2005-08-03 EpiCept Corporation Compositions for treating pain of the mucous membrane
US6648083B2 (en) 2000-11-02 2003-11-18 Schlumberger Technology Corporation Method and apparatus for measuring mud and formation properties downhole
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CN1527813A (zh) * 2001-04-02 2004-09-08 О 作为治疗剂的抗氧化剂硝基氧和亚硝氮碳基
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
IL149055A0 (en) 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
TW531966B (en) * 2002-05-20 2003-05-11 Mediatek Inc Phase lock loop with low static state phase error and calibration circuit
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
PL373903A1 (en) 2002-05-31 2005-09-19 H.Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US6662845B1 (en) 2002-06-19 2003-12-16 Newell Operating Company Roman shade with separated backing sheet
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
CN100453130C (zh) 2002-06-26 2009-01-21 精达制药公司 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞
AR040709A1 (es) * 2002-07-29 2005-04-13 Glaxo Group Ltd Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20050075679A1 (en) * 2002-09-30 2005-04-07 Gliner Bradford E. Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP1572163A1 (en) * 2002-12-11 2005-09-14 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment
WO2004056337A2 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AR042550A1 (es) * 2002-12-23 2005-06-22 Osmotica Argentina S A Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
US20050065219A1 (en) * 2003-03-27 2005-03-24 Lipton Stuart A. Treatment of demyelinating conditions
CA2525195A1 (en) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders
US20050124701A1 (en) * 2003-06-11 2005-06-09 Went Gregory T. Method of targeting a therapeutic agent
BRPI0411451A (pt) 2003-06-16 2006-07-18 Allergan Inc formas de dosagens orais de memantina
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
KR100524018B1 (ko) * 2003-07-25 2005-10-26 삼성전자주식회사 이동형 디스플레이장치 및 이동형 디스플레이 시스템
US20050037364A1 (en) * 2003-08-13 2005-02-17 International Business Machines Corporation Techniques for recording signals
CN1870984A (zh) 2003-10-22 2006-11-29 莫茨药物股份两合公司 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7553858B2 (en) 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
CA2551689A1 (en) 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer's disease
WO2005072705A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
AU2005215767A1 (en) * 2004-02-13 2005-09-01 Adamas Pharmaceuticals, Inc. Combination of an NMDA receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other CNS disorders
EP1734920A2 (en) * 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
AU2005215376B2 (en) 2004-02-18 2011-01-20 Sunovion Pharmaceuticals Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1740172A4 (en) 2004-03-19 2007-10-10 Axonyx Inc ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
AU2005265031A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7346382B2 (en) * 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
US20060052370A1 (en) * 2004-08-24 2006-03-09 Meyerson Laurence R Methods and compositions for treating nociceptive pain
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) * 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
JP2010523587A (ja) 2007-04-02 2010-07-15 パーキンソンズ インスティテュート 治療処置の副作用の低減のための方法および組成物

Also Published As

Publication number Publication date
US20160250161A1 (en) 2016-09-01
CN101247795A (zh) 2008-08-20
CA2604052A1 (en) 2006-11-16
DK1874282T3 (da) 2010-10-25
WO2006121560A2 (en) 2006-11-16
CA2604052C (en) 2014-07-08
CN101247795B (zh) 2012-02-01
BRPI0607017A2 (pt) 2009-08-04
US20160243095A1 (en) 2016-08-25
EP2243475B1 (en) 2016-01-13
IL186504A0 (en) 2008-01-20
US20160220545A1 (en) 2016-08-04
US20100311697A1 (en) 2010-12-09
US8293794B2 (en) 2012-10-23
EP2243475A1 (en) 2010-10-27
US20120264782A1 (en) 2012-10-18
US20160243035A1 (en) 2016-08-25
BRPI0607017B1 (pt) 2020-05-12
KR20070116996A (ko) 2007-12-11
US20120264783A1 (en) 2012-10-18
AU2006244297A1 (en) 2006-11-16
KR101406456B1 (ko) 2014-06-20
US8283379B2 (en) 2012-10-09
US8058291B2 (en) 2011-11-15
US20160250149A1 (en) 2016-09-01
PL1874282T3 (pl) 2011-04-29
BRPI0607017B8 (pt) 2021-05-25
ZA200709535B (en) 2008-11-26
US20110064804A1 (en) 2011-03-17
US8338485B2 (en) 2012-12-25
US20160243094A1 (en) 2016-08-25
MX2007012374A (es) 2008-02-22
WO2006121560A8 (en) 2007-04-26
US8580858B2 (en) 2013-11-12
US20160243093A1 (en) 2016-08-25
US20160243058A1 (en) 2016-08-25
WO2006121560A3 (en) 2007-03-15
US20060252788A1 (en) 2006-11-09
US20130131110A1 (en) 2013-05-23
US20180263914A1 (en) 2018-09-20
US8338486B2 (en) 2012-12-25
HK1106711A1 (en) 2008-03-20
EP1874282A2 (en) 2008-01-09
US20140134243A1 (en) 2014-05-15
US20120288560A1 (en) 2012-11-15
ATE481096T1 (de) 2010-10-15
US20150297537A1 (en) 2015-10-22
JP2008535867A (ja) 2008-09-04
DE602006016934D1 (de) 2010-10-28
RU2007140348A (ru) 2009-05-20
EP1874282B1 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
JP5666087B2 (ja) Ｃｎｓ関連疾患の治療のための方法及び組成物
US20090253728A1 (en) Methods and Compositions for Treating Nociceptive Pain
JP2007522249A (ja) 精神医学的状態の処置のための、ｎｍｄａレセプターアンタゴニストと、抗うつ薬であるｍａｏインヒビターまたはｇａｄｐｈインヒビターとの併用
JP2007522248A (ja) てんかんおよび他のｃｎｓ障害の処置のための、ｎｍｄａレセプターアンタゴニストと抗てんかん薬との組み合わせ
MX2007006120A (es) Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
ES2351709T3 (es) Método y composiciones para el tratamiento de trastornos de sistema nervioso.
HK1106711B (en) Methods and compositions for treatment of cns disorders
KR20070017136A (ko) 정신과적 질환의 치료를 위한 ｎｍｄａ 수용체 길항제와항우울제 ｍａｏ 억제제 또는 ｇａｄｐｈ 억제제의 조합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140912

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141210

R150 Certificate of patent or registration of utility model

Ref document number: 5666087

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250